Release date: 2016-08-18 On August 17, 2016, Beijing Berry and Kang Biotechnology Co., Ltd. (hereinafter referred to as “Berry and Kangâ€) and US BioNano Genomics (hereinafter referred to as “BioNanoâ€) announced the joint development of a new Irys® platform. A generation of chromosome structural variation analysis of clinical products, Berry and Kang will report to the State Food and Drug Administration (CFDA) for related product registration. Under the agreement, the two parties will jointly develop a high-throughput, high-resolution and easy-to-operate next-generation analysis system for chromosome structure variation detection. The system will consist of an Irys® platform-based device and test kit developed by Berry and Kang and BioNano. For specific clinical applications, Berry and Kang own the exclusive production and marketing rights of the system in China. In the field of scientific research, BioNano sells its scientific research version of the Irys® system to Chinese research institutions, including genomic research centers, government agencies, academic institutions, translation research institutions, and pharmaceutical companies. “In China, the clinical demand for detection of chromosome structural variation is growing rapidly. Existing detection methods, such as karyotyping, FISH and chip technology, have long experimental cycles and require a lot of manual manipulation, and usually cannot be genetically The mutation is fully tested. We believe that the Irys® platform is the most suitable solution, and the products based on this platform will make up for the shortcomings of the existing technology,†said Dr. Zhou Daixing, CEO of Berry and Kang. “As a new generation of chromosome structural variation analysis technology. Industry leader, BioNano is undoubtedly our ideal partner. It is the only company in the world with high-resolution detection technology for systematic analysis of chromosome structural variation. Currently, including high-throughput sequencing technology There is technology that has not yet achieved a comprehensive detection of pathogenic structural variations in the human genome." “By the innovation of product model, Berry and Kang have become the leaders of China's non-invasive prenatal screening (NIPT) market. We hope that relying on the new generation of chromosome structure variation analysis platform can help Berry and Kang in a wide range of genetic diseases and tumors. The same level of leadership is achieved in the field,†said Dr. Erik Holmlin, CEO of BioNano. “We work with the world's leading clinical diagnostics companies to advance human disease diagnosis to new levels through Irys® technology. This time with Berry and Kang Cooperation is one of the models." Source: Berry and Kang Qingdao Beautiful Skin Biotechnology Co., Ltd , https://www.hafilleresthetic.com